News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
760,098 Results
Type
Article (45721)
Company Profile (332)
Press Release (714027)
Multimedia
Podcasts (126)
Webinars (22)
Section
Business (212577)
Career Advice (2122)
Deals (36577)
Drug Delivery (136)
Drug Development (82783)
Employer Resources (177)
FDA (17074)
Job Trends (15447)
News (357858)
Policy (33638)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2748)
Accelerated approval (47)
Adcomms (26)
Allergies (177)
Alliances (52624)
ALS (213)
Alzheimer's disease (1822)
Antibody-drug conjugate (ADC) (462)
Approvals (17443)
Artificial intelligence (713)
Autoimmune disease (297)
Automation (58)
Bankruptcy (367)
Best Places to Work (11930)
BIOSECURE Act (20)
Biosimilars (222)
Biotechnology (221)
Bladder cancer (189)
Brain cancer (72)
Breast cancer (760)
Cancer (5881)
Cardiovascular disease (475)
Career advice (1805)
Career pathing (43)
CAR-T (343)
CDC (58)
Celiac Disease (3)
Cell therapy (930)
Cervical cancer (47)
Clinical research (71635)
Collaboration (2139)
Company closure (6)
Compensation (1402)
Complete response letters (80)
COVID-19 (2829)
CRISPR (115)
C-suite (1153)
Cystic fibrosis (158)
Data (7916)
Decentralized trials (3)
Denatured (45)
Depression (163)
Dermatology (86)
Diabetes (591)
Diagnostics (7213)
Digital health (57)
Diversity (13)
Diversity, equity & inclusion (45)
Drug discovery (333)
Drug pricing (203)
Drug shortages (33)
Duchenne muscular dystrophy (290)
Earnings (93761)
Editorial (67)
Employer branding (22)
Employer resources (157)
Events (124427)
Executive appointments (1115)
FDA (20853)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (16)
Frontotemporal dementia (34)
Funding (1778)
Gene editing (250)
Generative AI (62)
Gene therapy (756)
GLP-1 (1074)
Government (4838)
Grass and pollen (7)
Guidances (411)
Healthcare (19722)
HIV (83)
Huntington's disease (56)
IgA nephropathy (97)
Immunology and inflammation (292)
Immuno-oncology (94)
Indications (192)
Infectious disease (3176)
Inflammatory bowel disease (223)
Inflation Reduction Act (14)
Influenza (140)
Intellectual property (296)
Interviews (331)
IPO (17014)
IRA (51)
Job creations (3836)
Job search strategy (1502)
JPM (62)
Kidney cancer (19)
Labor market (100)
Layoffs (579)
Leadership (41)
Legal (8177)
Liver cancer (101)
Longevity (32)
Lung cancer (764)
Lymphoma (432)
Machine learning (63)
Management (63)
Manufacturing (1072)
MASH (186)
Medical device (14682)
Medtech (14807)
Mergers & acquisitions (20816)
Metabolic disorders (1510)
mRNA (229)
Multiple sclerosis (187)
NASH (17)
Neurodegenerative disease (423)
Neuropsychiatric disorders (105)
Neuroscience (3349)
Neurotech (1)
NextGen: Class of 2026 (6855)
Non-profit (4668)
Now hiring (78)
Obesity (704)
Opinion (301)
Ovarian cancer (222)
Pain (254)
Pancreatic cancer (304)
Parkinson's disease (365)
Partnered (34)
Patents (608)
Patient recruitment (682)
Peanut (66)
People (61879)
Pharmaceutical (67)
Pharmacy benefit managers (32)
Phase 1 (22493)
Phase 2 (31531)
Phase 3 (23372)
Pipeline (8736)
Policy (324)
Postmarket research (2587)
Preclinical (9674)
Press Release (71)
Prostate cancer (303)
Psychedelics (54)
Radiopharmaceuticals (343)
Rare diseases (1088)
Real estate (6300)
Recruiting (70)
Regulatory (26033)
Reports (56)
Research institute (2555)
Resumes & cover letters (365)
Rett syndrome (39)
RNA editing (24)
RSV (89)
Schizophrenia (179)
Series A (303)
Series B (217)
Service/supplier (14)
Sickle cell disease (113)
Special edition (23)
Spinal muscular atrophy (167)
Sponsored (49)
Startups (3907)
State (2)
Stomach cancer (18)
Supply chain (127)
Tariffs (87)
The Weekly (78)
Vaccines (1136)
Venture capital (113)
Weight loss (457)
Women's health (127)
Worklife (20)
Date
Today (210)
Last 7 days (945)
Last 30 days (3662)
Last 365 days (31035)
2026 (12581)
2025 (30957)
2024 (36210)
2023 (41133)
2022 (52398)
2021 (56991)
2020 (55610)
2019 (48407)
2018 (36438)
2017 (33539)
2016 (33138)
2015 (39357)
2014 (32943)
2013 (27987)
2012 (30243)
2011 (30849)
2010 (28811)
Location
Africa (782)
Alabama (95)
Alaska (7)
Arizona (361)
Arkansas (16)
Asia (42404)
Australia (7062)
California (13458)
Canada (3774)
China (1372)
Colorado (578)
Connecticut (588)
Delaware (415)
Europe (93432)
Florida (1993)
Georgia (439)
Hawaii (3)
Idaho (65)
Illinois (1081)
India (90)
Indiana (609)
Iowa (24)
Japan (545)
Kansas (135)
Kentucky (53)
Louisiana (42)
Maine (75)
Maryland (1604)
Massachusetts (9712)
Michigan (392)
Minnesota (736)
Mississippi (7)
Missouri (156)
Montana (36)
Nebraska (29)
Nevada (146)
New Hampshire (91)
New Jersey (3541)
New Mexico (31)
New York (3508)
North Carolina (1732)
North Dakota (11)
Northern California (6719)
Ohio (408)
Oklahoma (25)
Oregon (45)
Pennsylvania (2688)
Puerto Rico (30)
Rhode Island (51)
South America (1170)
South Carolina (86)
South Dakota (2)
Southern California (5307)
Tennessee (214)
Texas (2146)
United States (47685)
Utah (405)
Vermont (1)
Virginia (329)
Washington D.C. (81)
Washington State (1087)
West Virginia (4)
Wisconsin (139)
Wyoming (2)
760,098 Results for "siga technologies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
SIGA Reports Financial Results for Three Months Ended March 31, 2026 and Provides Business Update
May 8, 2026
·
9 min read
Press Releases
SIGA to Host Business Update Call on May 7, 2026, Following Release of First-Quarter 2026 Financial Results
April 30, 2026
·
1 min read
Press Releases
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2025 and Provides Business Update
March 11, 2026
·
11 min read
Press Releases
SIGA to Host Business Update Call on March 10, 2026, Following Release of 2025 Financial Results
March 3, 2026
·
1 min read
Press Releases
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2025
November 6, 2025
·
10 min read
Press Releases
SIGA to Host Business Update Call on November 6, 2025 Following Release of Third-Quarter 2025 Results
October 31, 2025
·
1 min read
Biotech Beach
Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors
Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”) today announced that it entered into a collaboration agreement with SIGA Technologies (Nasdaq: SIGA) in the first quarter of 2024, to support the development of Calidi’s systemic and targeted RTNova (CLD-400) virotherapy platform, which has the potential to provide a universal treatment for all tumor types.
June 10, 2024
·
6 min read
Business
SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results
SIGA Technologies, Inc. announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, May 7, 2024.
May 1, 2024
·
3 min read
Business
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023
SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2023.
March 12, 2024
·
12 min read
Pharm Country
SIGA Announces Agreement to Sell TPOXX® to ASEAN Member States
SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on global health and infectious diseases, announced an agreement to expand access to TPOXX to the member states in the Association of Southeast Asian Nations, a political and economic union in the region.
June 17, 2024
·
8 min read
1 of 76,010
Next
